Panion & BF Biotech Inc.

As of June 30, 2026, Panion & BF Biotech Inc. carries a market capitalization of 5.22B, placing it among publicly traded companies globally. Its enterprise value stands at 5.35B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Panion & BF Biotech Inc.'s next confirmed earnings release is scheduled for November 17, 2026.

As of June 30, 2026, Panion & BF Biotech Inc. has 85.74M shares outstanding.

As of June 30, 2026, Panion & BF Biotech Inc. trades at a trailing price-to-earnings ratio of 24.28. The price-to-sales ratio is 2.47, and the price-to-book ratio stands at 2.79.

As of June 30, 2026, Panion & BF Biotech Inc. trades at an EV/EBITDA multiple of 11.81 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.54 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 16.89 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Panion & BF Biotech Inc. trades at an EV/FCF ratio of 26.01, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 5.35B versus a market cap of 5.22B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Panion & BF Biotech Inc. maintains a current ratio of 1.32, meaning it holds 1.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 32.18, indicating elevated leverage, while an interest coverage ratio of 32.34 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Panion & BF Biotech Inc. posted a return on equity (ROE) of 11.63, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 8.57 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 6.69, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 9.03, useful for judging operating efficiency across full business cycles. The company generates approximately 3.91M in revenue per employee across its workforce of 540.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.78 indicates how many times Panion & BF Biotech Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Panion & BF Biotech Inc. recorded 104.73M in income tax expense. That works out to an effective tax rate of 32.77, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 319.56M, leaving 214.83M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Panion & BF Biotech Inc.'s stock has declined approximately 23.86% over the past 52 weeks. The 50-day moving average sits at 55.69, while the 200-day moving average is 60.74.

Over the twelve months ended June 30, 2026, Panion & BF Biotech Inc. generated 2.11B in revenue and converted that into 214.83M in net income, yielding earnings per share of 2.51. EBITDA reached 453.33M, while operating income came in at 318.69M.

As of June 30, 2026, Panion & BF Biotech Inc. holds 471.42M in cash and equivalents against 603.26M in total debt, resulting in a net debt position of 94.09M. Total book value stands at 1.87B, with working capital of 355.56M providing operational flexibility.

Panion & BF Biotech Inc. produced 340.64M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -144.22M in capital expenditures, free cash flow totaled 196.43M - equivalent to 2.29 per share.

Over the twelve months ended June 30, 2026, Panion & BF Biotech Inc. posted a gross margin of 52.85, reflecting its pricing power and cost economics. The operating margin of 15.11 and net profit margin of 10.19 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Panion & BF Biotech Inc. paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 3.76, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 4.65, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Panion & BF Biotech Inc. shareholders.

Panion & BF Biotech Inc.'s most recent stock split took place on August 6, 2021 with a 745:756 split ratio.

As of June 30, 2026, Panion & BF Biotech Inc. has an Altman Z-Score of 3.49, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.